Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

被引：46
|
作者：
Cho, B. C. [1 ]
Felip, E. [2 ,3 ]
Spira, A. I. [4 ]
Girard, N. [5 ,6 ]
Lee, J. S. [7 ]
Lee, S. H. [8 ]
Ostapenko, Y. V. [9 ]
Danchaivijitr, P. [10 ]
Liu, B. [11 ]
Alip, A. [12 ]
Korbenfeld, E. P. [13 ]
Dias, J. [14 ]
Sun, T. [15 ]
Martinez, M.
Bauml, J. M. [16 ]
Shreeve, M. [17 ]
Sethi, S. [16 ]
Knoblauch, R. E. [16 ]
Hayashi, H. [18 ]
Lu, S. [19 ]
机构：
[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] Virginia Canc Specialists, Fairfax, VA USA
[5] Inst Thorax Curie Montsouris, Inst Curie, Paris, France
[6] UVSQ, Univ Paris Saclay, Versailles, France
[7] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea
[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[9] Natl Canc Inst, Kiev, Ukraine
[10] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[12] Univ Malaya Med Ctr, Kuala Lumpur, Malaysia
[13] Hosp Britanico Buenos Aires, Buenos Aires, DF, Argentina
[14] Barretos Canc Hosp, Barretos, Brazil
[15] Janssen R&D, Raritan, NJ USA
[16] Janssen R&D, Spring House, PA USA
[17] Janssen R&D, San Diego, CA USA
[18] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[19] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA14
引用
收藏
页码：S1306 / S1306
页数：1
相关论文
共 50 条
  • [1] Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
    Lu, S.
    Cho, B. C.
    Lee, J-S.
    Lee, S-H.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Xiong, H.
    How, S. H.
    Chang, G-C.
    Yang, J. C-H.
    Yoshioka, H.
    Xia, K.
    Martinez, M.
    Bauml, J. M.
    Sethi, S.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1661
  • [2] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
    Passaro, A.
    Cho, B. C.
    Wang, Y.
    Melosky, B.
    Califano, R.
    Lee, S-H.
    Girard, N.
    Reckamp, K. L.
    Takahashi, T.
    Felip, E.
    Gentzler, R. D.
    Popat, S.
    William, W. Nassib, Jr.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Garcia-Campelo, M. R.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
  • [3] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [4] Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Nonsmall Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial (Previously presented at ESMO Congress 2023, FPN:LBA14, Byoung Chul Cho et al. - Reused with permission.)
    Schuler, Martin
    Cho, Byoung Chul
    Felip, Enriqueta
    Spira, Alexander
    Girard, Niolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yuriy
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao, Josiane
    Sun, Tao
    Martinez, Melissa
    Bauml, Joshua
    Shreeve, Martin
    Sethi, Seema
    Knoblauch, Roland
    Hayashi, Hidetoshi
    Lu, Shun
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 260 - 261
  • [5] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
    Nguyen, D.
    Besse, B.
    Cho, B. C.
    Lee, S. -H.
    Lee, K. H.
    Lu, S.
    Cheng, Y.
    Yao, Y.
    Girard, N.
    Lin, C. -C.
    Felip, E.
    Aguilar, A.
    Charoentum, C.
    Cruz, F. J. S. M.
    Majem, M.
    Lim, C. S.
    Akamatsu, H.
    Hayashi, H.
    Yang, J. C. -H.
    Kowalyszyn, R.
    Tiscoski, K.
    Franke, F.
    Ponomarenko, D.
    Arslan, C.
    Forster, M.
    Urban, D.
    Misch, D.
    Delmonte, A.
    Montes, L. V. G.
    Gadgeel, S. M.
    Cruz-Correa, M.
    Peguero, J.
    Rousey, S.
    Gaffar, Y.
    Owen, S.
    Schuchard, J.
    Diels, J.
    Sermon, J.
    Sun, T.
    Ennis, M.
    Fennema, E.
    Daksh, M.
    Sethi, S.
    Bauml, J. M.
    Garcia Campelo, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
  • [6] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
    Cho, Byoung Chul
    Felip, Enriqueta
    Hayashi, Hidetoshi
    Thomas, Michael
    Lu, Shun
    Besse, Benjamin
    Sun, Tao
    Martinez, Melissa
    Sethi, Seema N.
    Shreeve, S. Martin
    Spira, Alexander, I
    FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
  • [7] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [8] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
  • [9] Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer
    Ku, Li-Jung Elizabeth
    Tsai, Jui-Hung
    Chen, Li-Jun
    Yang, Szu-Chun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [10] Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
    Besse, B.
    Lee, S-H.
    Lu, S.
    Stroyakovskiy, D.
    Yazici, O.
    Rodriguez Cid, J. R.
    Hayashi, H.
    Nguyen, D.
    Yang, J. C-H.
    Gottfried, M.
    Gelatti, A. C.
    Owen, S.
    Ou, S-H. I.
    Ennis, M.
    Sethi, S.
    Bauml, J. M.
    Zhang, J.
    Curtin, J. C.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 : 1245 - 1246
12345